BioNTech (BNTX) Competitors

GSK (NYSE:GSK) and BioNTech (NASDAQ:BNTX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

Which has better valuation & earnings, GSK or BNTX?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$31.53B	2.46	$3.29B	$1.94	19.49
BioNTech	$2.98B	8.93	-$719.92M	-$3.40	-32.54

Do analysts prefer GSK or BNTX?

GSK presently has a consensus price target of $37.38, suggesting a potential downside of 1.16%. BioNTech has a consensus price target of $137.91, suggesting a potential upside of 24.64%. Given BioNTech's stronger consensus rating and higher possible upside, analysts plainly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.11
BioNTech	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.83

Which has more volatility and risk, GSK or BNTX?

GSK has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, BioNTech has a beta of 1.29, meaning that its stock price is 29% more volatile than the S&P 500.

Does the media favor GSK or BNTX?

In the previous week, GSK had 4 more articles in the media than BioNTech. MarketBeat recorded 18 mentions for GSK and 14 mentions for BioNTech. BioNTech's average media sentiment score of 0.99 beat GSK's score of 0.68 indicating that BioNTech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	7 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
BioNTech	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Is GSK or BNTX more profitable?

GSK has a net margin of 9.89% compared to BioNTech's net margin of -27.37%. GSK's return on equity of 48.82% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	9.89%	48.82%	11.15%
BioNTech	-27.37%	-3.94%	-3.41%

Do institutionals and insiders have more ownership in GSK or BNTX?

15.7% of GSK shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 19.2% of BioNTech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

GSK beats BioNTech on 9 of the 16 factors compared between the two stocks.